Search
Olopatadine
go.drugbank.com/drugs/DB00768ApprovedAn ophthalmic solution of olopatadine was approved by the FDA and European Union for the treatment of seasonal and perennial allergic conjunctivitis in 1996 and 2002, respectively.
Glycopyrronium
go.drugbank.com/drugs/DB00986ApprovedInvestigationalVet approved[A233565] Glycopyrronium was originally granted FDA approval on 11 August 1961.[L33090]
Centanafadine
go.drugbank.com/drugs/DB14841ApprovedInvestigational[L63934] The FDA approved centanafadine on July 24, 2026, for the treatment of ADHD in adults and pediatric patients 6 years of age and older weighing at least 20 kg; use is not recommended below that
Mobocertinib
go.drugbank.com/drugs/DB16390ApprovedInvestigationalWithdrawn[L38319] Mobocertinib, under the brand name Exkivity (Takeda Pharmaceuticals Inc.), was granted accelerated approval by the FDA in September 2021 for the treatment of locally advanced or metastatic
Rotigotine
go.drugbank.com/drugs/DB05271ApprovedInvestigationalIt was approved by the European Medicines Agency in 2006 and by the FDA in 2007.
Melarsomine
go.drugbank.com/drugs/DB11528ExperimentalVet approvedIt is the only FDA-approved treatment for adult heartworm infection in dogs, however, is is not approved for use in dogs with late-stage infection.
Emricasan
go.drugbank.com/drugs/DB05408InvestigationalEmricasan is the first caspase inhibitor tested in human which has received orphan drug status by FDA.
Tifuvirtide
go.drugbank.com/drugs/DB05413InvestigationalIt has received fast-track designation from the FDA and is in Phase I/II clinical testing.
Rimacalib
go.drugbank.com/drugs/DB12571InvestigationalRimacalib has been used in trials studying the treatment of Rheumatoid Arthritis (RA).
Cannabidivarin
go.drugbank.com/drugs/DB14050InvestigationalCannabidivarin, also known as cannabidivarol or CBDV, is a non-psychoactive cannabinoid found within DB14009. It is one of over 100 cannabinoids identified from the Cannabis plant that can modulate the physiological activity of cannabis,...